Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Pirfewel 801
Pirfewel 801 is an orally administered antifibrotic medication containing Pirfenidone 801 mg, specifically developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF). By reducing lung scarring and inflammation, Pirfewel 801 helps slow disease progression, preserve lung function, and improve overall respiratory health.
Uses of Pirfewel 801
Pirfewel 801 is indicated for the treatment of:
Idiopathic Pulmonary Fibrosis (IPF)
Progressive pulmonary fibrosis
Other fibrotic lung diseases (investigational use under specialist guidance)
Benefits of Pirfewel 801
Slows Pulmonary Fibrosis Progression: Inhibits excessive scarring of lung tissue
Reduces Inflammation & Fibrosis: Blocks key pathways involved in fibrotic lung disease
Preserves Lung Function: Helps maintain respiratory capacity and oxygen exchange
Reduces Disease Exacerbations: Lowers the risk of acute worsening in IPF patients
Well-Tolerated with Proven Efficacy: Established safety in long-term therapy
Mechanism of Action of Pirfewel 801
Pirfenidone exerts its antifibrotic and anti-inflammatory effects by inhibiting pro-fibrotic cytokines, particularly TGF-β and TNF-α, which play a central role in lung tissue scarring. By reducing fibroblast proliferation and collagen synthesis, it slows the progression of lung fibrosis and helps preserve pulmonary function.